Activities of β-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 767-770

  Visalli, Melissa A ^a   Jacobs, Michael R ^b   Moore, Terrance D ^c   Renzi, Frank A ^d   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c SmithKline Beecham   (United States)

^d SmithKline Beecham Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CLAVULANIC ACID; IMIPENEM; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TICARCILLIN;

ACINETOBACTER; ACINETOBACTER CALCOACETICUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

EID: 0030891937     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.767     Document Type: Article

References (29)

1. Appelbaum, P. C., S. K. Spangler, and L. Sollenberger. 1986. Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome. J. Antimicrob. Chemother. 18:675-679.
2. Appelbaum, P. C., S. K. Spangler, and T. Tamarree. 1988. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin. Chemotherapy (Basel) 34:40-45.
3. Appelbaum, P. C., J. Tamim, G. A. Pankuch, and R. C. Aber. 1983. Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and aztreonam. Chemotherapy (Basel) 29:337-344.
4. Appelbaum, P. C., J. Tamim, J. Stavitz, R. C. Aber, and G. A. Pankuch. 1982. Sensitivity of 341 non-fermentative gram-negative bacteria to seven beta-lactam antibiotics. Eur. J. Clin. Microbiol. 1:159-165.
5. Bergogne-Berezin, E., and M. L. Joly-Guillou. 1985. An underestimated nosocomial pathogen, Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 16:535-538.
6. Bergogne-Berezin, E., and M. L. Joly-Guillou. 1986. Comparative activity of imipenem, ceftazidime and cefotaxime against Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 18(Suppl. E):35-39.
7. Fass, R. J., and J. Barnishan. 1980. In vitro susceptibilities of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents. Rev. Infect. Dis. 2:841-853.
8. Hoban, D. J., R. N. Jones, N. Yamane, R. Frei, A. Trilla, and A. C. Pignatari. 1993. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn. Microbiol. Infect. Dis. 17:299-305.
9. Husson, M. O., D. Izard, L. Bouillet, and H. Leclerc. 1985. Comparative in-vitro activity of ciprofloxacin against non-fermenters. J. Antimicrob. Chemother. 15:457-462.
10. Joly-Guillou, M. L., E. Bergogne-Bérézin, and N. Moreau. 1987. Enzymatic resistance to β-lactams and aminoglycosides in Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 20:773-775.
11. Kitzis, M. D., F. W. Goldstein, R. Labia, and J. F. Acar. 1983. Activité du sulbactam et de l'acide clavulanique, seuls et associés, sur Acinetobacter calcoaceticus. Ann. Inst. Pasteur Microbiol. 134A:163-168.
12. Kuah, B. G., G. Kumarasinghe, J. Doran, and H. R. Chang. 1994. Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore. Antimicrob. Agents Chemother. 38:2502-2503.
13. Lortholary, O., J.-Y. Fagon, A. B. Hoi, M. A. Slama, J. Pierre, P. Giral, R. Rosenzweig, L. Gutmann, M. Safar, and J. Acar. 1995. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin. Infect. Dis. 20:790-796.
14. MacGowan, A. P., K. E. Bowker, K. A. Bedford, H. A. Holt, D. S. Reeves, and A. Hedges. 1995. The comparative inhibitory and bactericidal activities of meropenem and imipenem against Acinetobacter spp. and Enterobacteriaceae resistant to second generation cephalosporins. J. Antimicrob. Chemother. 35:333-337.
15. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard. NCCLS publication no. M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Obana, Y., and T. Nishino. 1990. In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 26:677-682.
17. Obara, M., and T. Nakae. 1991. Mechanism of resistance to β-lactam antibiotics in Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 28:791-800.
18. Rolston, K. V. I., and G. P. Bodey. 1986. In vitro susceptibility of Acinetobacter species to various antimicrobial agents. Antimicrob. Agents Chemother. 30:769-770.
19. Sato, K., and T. Nakae. 1991. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J. Antimicrob. Chemother. 28:35-45.
20. Seifert, H., R. Baginski, A. Schulze, and G. Pulrerer. 1993. Antimicrobial susceptibility of Acinetobacter species. Antimicrob. Agents Chemother. 37: 750-753.
21. Shalit, I., M. Dan, R. Gutman, A. Gorea, and S. A. Berger. 1990. Cross resistance to ciprofloxacin and other antimicrobial agents among clinical isolates of Acinetobacter calcoaceticus biovar anitratus. Antimicrob. Agents Chemother. 34:494-495.
22. Simor, A. E., L. Louie, and M. Louie. 1994. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 13:521-523.
23. Suh, B., T. Shapiro, R. Jones, V. Satishchandran, and A. L. Truant. 1995. In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn. Microbiol. Infect. Dis. 21:111-114.
24. Tankovic, J., P. Legrand, G. De Gatines, V. Chemineau, C. Brun-Buisson, and J. Duval. 1994. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J. Clin. Microbiol. 32:2677-2681.
25. Tilley, P. A. G., and F. J. Roberts. 1994. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin. Infect. Dis. 18:896-900.
26. Urban, C., E. Go, N. Mariano, B. J. Berger, I. Avraham, D. Rubin, and J. J. Rahal. 1993. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J. Infect. Dis. 167:448-451.
27. Vallée, E., M. L. Joly-Guillou, and E. Bergogne-Bérézin. 1990. Activité comparative de l'imipénème, du céfotaxime et de la ceftazidime vis-à-vis d'Acinetobacter calcoaceticus. Presse Med. 19:588-591.
28. von Graevenitz, A. 1995. Acinetobacter, Alcaligenes, Moraxella, and other nonfermemative gram-negative bacteria, p. 520-532. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
29. Von Graevenitz, A., and C. Bucher. 1982. The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans. Infection 10:293-298.